{"id":206573,"name":"ANTHEIA","slug":"antheia","state":"CA","country":"United States of America","description":"Science and technology company developing next generation plant-inspired medicines","totalSpending":1080000,"filings":23,"yearlySpending":[{"year":2020,"income":120000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":240000},{"year":2025,"income":0}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"DEF","display":"Defense"}],"firms":["INVARIANT LLC"],"lobbyists":["BENJAMIN KLEIN","KATHRYN WISE","ANNABELL STOKES","CHRISTOPHER GILLOTT","STEPHEN WEYLER","JESSICA HATCHER"],"govEntities":["Executive Office of the President (EOP)","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","Natl Economic Council (NEC)","SENATE","Office of Policy Development","Defense, Dept of (DOD)","Food & Drug Administration (FDA)","Office of Management & Budget (OMB)","Office of Science & Technology Policy (OSTP)","Export-Import Bank of the United States (EXIM Bank)"],"sampleDescriptions":["Issues related to the pharmaceutical supply chain.","Encourage support for technology solutions to shift the pharmaceutical supply chain back to the U.S.; highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients.","Encourage support for technology solutions to shift the pharmaceutical supply chain back to the U.S.; highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients.","Encourage support for technology solutions to shift the pharmaceutical supply chain back to the U.S.; highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients.","Highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients. Encourage support for federal loan programs for technology to strengthen our domestic supply chain for pharma"]}